Table 3.
Incidence of Hepatocellular Carcinoma (%) After Liver Biopsy in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease
| Marker | Category | Number of patients (%) | 1 y | 3 y | 5 y | 10 y | 15 y |
|---|---|---|---|---|---|---|---|
| aMAP score | 0–50 | 583 (50.7) | 0 | 0 | 0 | 0 | 0 |
| 50–60 | 438 (38.1) | 0 | 0.3 | 1.0 | 4.0 | 6.2 | |
| 60–100 | 130 (11.3) | 0.8 | 2.7 | 8.5 | 16.0 | 16.0 | |
| FIB-4 index | <1.30 | 575 (49.2) | 0 | 0 | 0 | 0 | 0.6 |
| 1.30–2.67 | 399 (34.1) | 0 | 0.3 | 0.7 | 1.5 | 3.9 | |
| >2.67 | 195 (16.7) | 0.6 | 1.9 | 6.9 | 17.4 | 17.4 | |
| ALBI score | ≤ −2.60 | 985 (86.6) | 0 | 0.1 | 0.4 | 1.9 | 2.7 |
| > −2.60 | 153 (13.4) | 0.7 | 2.5 | 8.3 | 11.3 | 11.3 |
Patients With F0–F2 Liver Fibrosis (n = 1170).